Reuters (10/12) (10/12) reports that the Food and Drug Administration on Thursday issued a safety alert, warning that abusing Endo Pharmaceuticals’ pain treatment, Opana ER (oxymorphone hydrochloride extended-release tablets), which is administered orally, by injecting intravenously, could result in a severe, sometimes fatal, blood disorder. The agency said it has received reports in which persons abusing the prescription painkiller, by injecting it directly into their bloodstreams, developed thrombotic thrombocytopenic purpura (TTP), which ultimately, resulted in cases of kidney failure, some of which required dialysis. The FDA added that at least one of the TTP cases reported has since resulted in death.